Drugs / AP026
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06143423 | May → Jul 2023 | type 2 diabetes mellitus | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06143423 ↗ |
| Known as | TQA2226 | “AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.” NCT06143423 ↗ |
| Modality | Protein / enzyme biologic | “AP026 (TQA2226) for injection is a GLP-1-FGF21-Fc bifunctional fusion protein.” NCT06143423 ↗ |